Anti-viral Active Air-Purifying Respirator with Photocatalytic Microreactor to Prevent Airborne Diseases
带光催化微反应器的抗病毒主动空气净化呼吸器可预防空气传播疾病
基本信息
- 批准号:10385625
- 负责人:
- 金额:$ 24.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
The potential for an epidemic or pandemic caused by a high-impact respiratory pathogen is increasing. Studies
prior to the COVID-19 outbreak show that the frequency of outbreaks of newly emerging diseases rose, which
has exacerbated since the pandemic started. Respiratory protective masks are used whenever airborne
contaminants such as dust, fumes, smoke, and mists are present in the air. The contaminants also include
airborne bacteria, viruses, and fungi. Currently, most commercially available untethered protective masks are
designed for surgical or industrial safety and may provide adequate protection from airborne contaminants but
do so through particle filtering. Therefore, most masks do not kill the pathogens to protect the wearers. Hence,
while using an active respirator, the filtered pathogens, which are alive and infectious, may enter the respiratory
tract overtime or spread by touch. The current active respirators are bulky, heavy, and designed for 2-4 hours of
use. In brief, the protective masks are not designed for prolonged daily use by untrained users. Until the outbreak
of COVID-19, the necessity of an anti-pathogenic wearable respirator was not as significant as it is now. This
COVID-19 has exposed our lack of preparedness in providing a safe working environment for the frontline
workers during the respiratory pandemic. Most current protective respirators address only part of the desired
solution. A working solution needs to combine all the critical requirements, such as high filtration (≥ 99%) for
nanometer-scale particles, pathogens-neutralization, moisture dissipation, eco-friendliness, and comfortable
prolonged use. The proposed R&D effort addresses a wearable anti-pathogenic respirator's critical need for
prolonged use by trained or untrained users. We propose designing and developing an active, untethered, anti-
pathogen full-face breathing mask with an integrated photocatalytic microreactor that can neutralize all
microorganisms, including viruses SARS-CoV-2. Although the proposed system contains all the components of
a portable respirator, the components are miniaturized and integrated into a full-face mask. Hence, the system
is referred to as a full-face mask in this proposal. The proposed full-face mask intakes surrounding air filters out
particles as small as 100 nm (size of a single SARS-CoV-2 viral particle), passes the air through an integrated
photocatalytic microreactor killing all the microorganisms, and volatile organic chemicals (VOCs), and supply
clean air to the user. The mask also works as a defense against the threat of contamination of ventilation systems
by bioterrorism. The mask is completely untethered and designed to run for 8-10 hours with a single charge. The
active-powered mask can save the wearer from airborne pathogens while maintaining visibility and comfort.
项目概要/摘要
由高影响呼吸道病原体引起流行病或大流行的可能性正在增加。
在 COVID-19 爆发之前表明,新出现的疾病爆发的频率上升,这
自大流行开始以来,情况一直在恶化,只要在空中飞行,就需要佩戴呼吸防护口罩。
空气中存在灰尘、烟雾、烟雾和薄雾等污染物。
目前,大多数市售的无线防护口罩都是空气传播的细菌、病毒和真菌。
专为手术或工业安全而设计,可提供足够的保护,防止空气中的污染物,但
因此,大多数口罩不会杀死病原体来保护佩戴者。
使用主动式呼吸器时,过滤后的活的且具有传染性的病原体可能会进入呼吸道
目前的主动式呼吸器体积大、重,设计时可使用 2-4 小时。
简而言之,在疫情爆发之前,防护口罩不适合未经培训的使用者长时间日常使用。
在 COVID-19 爆发期间,抗病可穿戴式呼吸器的必要性并不像现在那么重要。
COVID-19 暴露了我们在为前线提供安全工作环境方面缺乏准备
大多数当前的防护呼吸器只能满足呼吸道大流行期间的部分要求。
有效的解决方案需要结合所有关键要求,例如高过滤(≥ 99%)。
纳米级颗粒,中和病原体,排湿,环保,舒适
拟议的研发工作解决了可穿戴式抗病原呼吸器的关键需求。
我们建议设计和开发一种主动的、不受束缚的、抗干扰的产品。
带有集成光催化微反应器的病原体全脸呼吸面罩,可以中和所有病原体
尽管所提出的系统包含病毒 SARS-CoV-2 的所有组件。
便携式呼吸器的组件被小型化并集成到全面罩中,因此,该系统。
在本提案中,提议的全面罩进气口周围的空气过滤器被称为全面罩。
小至 100 nm 的颗粒(单个 SARS-CoV-2 病毒颗粒的大小),使空气通过集成的
光催化微反应器杀死所有微生物和挥发性有机化学物质(VOC),并供应
为用户提供洁净的空气,该面罩还可以防御通风系统污染的威胁。
该面罩完全不受束缚,一次充电可运行 8-10 小时。
主动供电面罩可以保护佩戴者免受空气中病原体的侵害,同时保持能见度和舒适度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M Arifur Rahman其他文献
M Arifur Rahman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
m6A甲基化修饰NOX4在病毒性心肌炎心肌纤维化中的作用及清心饮的干预研究
- 批准号:82374357
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
艾叶活性成分Artemvulactone E靶向MAMDC2抑制STING/NF-κB通路抗疱疹病毒性脑炎的机制研究
- 批准号:82373917
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
牛病毒性腹泻病毒激活NLRP3炎症体介导Gasdermin D剪切诱发炎症反应的分子机制研究
- 批准号:32302845
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
免扩增核酸定量检测技术研究及其在发热儿童细菌与病毒性感染快速鉴别中的应用
- 批准号:22304040
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Calpain通过MYC-DHODH促进铁死亡介导早期心肌损伤在病毒性心肌炎中的作用及机制研究
- 批准号:82370361
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Cell-derived extracellular vesicle mediated epigenetic silencing of HIV in the brain
细胞源性细胞外囊泡介导大脑中HIV的表观遗传沉默
- 批准号:
10748545 - 财政年份:2023
- 资助金额:
$ 24.35万 - 项目类别:
Characterization of JT-4-173, a Potent Antiviral that Inhibits HIV-1 by a Novel Mechanism of Action
JT-4-173 的表征,一种通过新颖作用机制抑制 HIV-1 的强效抗病毒药物
- 批准号:
10762518 - 财政年份:2023
- 资助金额:
$ 24.35万 - 项目类别:
Long-acting multi prevention implant for 2-year contraception and HIV PrEP
用于 2 年避孕和 HIV PrEP 的长效多重预防植入物
- 批准号:
10619811 - 财政年份:2023
- 资助金额:
$ 24.35万 - 项目类别:
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists
严重Covid-19和病毒性过度炎症损伤的新靶点和新疗法:肾酶和肾酶激动剂
- 批准号:
10759030 - 财政年份:2023
- 资助金额:
$ 24.35万 - 项目类别:
Regulation of and Target Recognition by Protein Arginine Methyltransferase 1 (PRMT1)
蛋白质精氨酸甲基转移酶 1 (PRMT1) 的调节和目标识别
- 批准号:
10653465 - 财政年份:2023
- 资助金额:
$ 24.35万 - 项目类别: